

**Dataset Integrity Check  
for the Chronic Prostatitis  
Collaborative Research Network –  
Ciprofloxacin-Tamsulosin Study,  
CPCR N RCT#1**



**Prepared by**

**RTI International**  
3040 Cornwallis Road  
Research Triangle Park, NC 27709-2194  
**March 28, 2012**

## Revision History

Version	Author/Title	Date	Comments
1.0	Susan M. Rogers	March 28, 2012	

# Table of Contents

1	Introduction .....	1
2	Background.....	2
3	Archived Datasets.....	3
4	DSIC Analysis .....	4
5	DSIC Results .....	5
6	Primary and Secondary Outcomes.....	6
7	Summary.....	10
8	References .....	11
	Appendix A: Stata Code and Output for DSIC Tabulations .....	12

Table 1: Baseline Characteristics by Individual Treatment Groups (Table 2)..... 5

Table 2: Secondary end points: Changes from baseline to 6 weeks, main effects (Table 4). ..... 8

Table 3: Secondary end points: Changes from baseline to 6 weeks in individual groups (Table 5). ..... 9

Figure 1: Mean values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score (potential of 43 points) over time for the 4 individual treatment groups (Figure 2). 6

# 1 Introduction

As a partial check of the integrity of the CPCRN RCT#1-CiproFlomax dataset archived in the NIDDK data repository, a set of tabulations was performed to verify that published results can be reproduced using the archived dataset. Analyses were performed to duplicate selected results for the data published by Alexander et al [1] in the *Annals of Internal Medicine* in 2004. The results of this dataset integrity check (DSIC) are described below. The Stata code and output for our DSIC tabulations are included in Attachment A [2].

The intent of this DSIC is to provide confidence that the data distributed by the NIDDK repository is a true copy of the study data. Our intent is not to assess the integrity of the statistical analyses reported by study investigators. As with all statistical analyses of complex datasets, complete replication of a set of statistical results should not be expected on a first (or second) exercise in secondary analysis. This occurs for a number of reasons including differences in the handling of missing data, restrictions on cases included in samples for a particular analysis, software coding used to define complex variables, etc. Experience suggests that most discrepancies can ordinarily be resolved by consultation with the study data coordinating center (DCC), however this process is labor-intensive for both DCC and Repository staff. It is thus not our policy to resolve every discrepancy that is observed in an integrity check. Specifically, we do not attempt to resolve minor or inconsequential discrepancies with published results or discrepancies that involve complex analyses, unless NIDDK Repository staff suspect that the observed discrepancy suggests that the dataset may have been corrupted in storage, transmission, or processing by repository staff. We do, however, document in footnotes to the integrity check those instances in which our secondary analyses produced results that were not fully consistent with those reported in the target publication.

## 2 Background

The Chronic Prostatitis Collaborative Research Network CiproFlomax study was a multicenter randomized clinical trial to evaluate the efficacy of ciprofloxacin, tamsulosin, the combination of ciprofloxacin and tamsulosin, or placebo in reducing symptoms associated with chronic prostatitis-chronic pelvic pain in men. Men were randomly assigned to 500mg twice daily of ciprofloxacin, 0.4 mg daily of tamsulosin, a combination of the two drugs, or placebo treatment for 6 weeks. The primary outcome was a change on the NIH Chronic Prostatitis Symptom Index (NIH-CPSI, range 0-43 with higher scores indicating more severe symptoms) from baseline to 6 weeks. (To be eligible for the study, men were required to have a NIH-CPSI score of at least 15 at the time of randomization). Secondary outcomes included changes in the pain, voiding, and quality of life subscales of the NIH-CPSI; physical and mental summary scores on the Medical Outcomes 12-Item Short-Form Health Survey; and a 7-point global response assessment (GRA) of self-reported change in chronic prostatitis-related symptoms at 6 weeks. A total of 196 participants were randomized. The paper by Alexander et al. provides the main study results for the efficacy trial.

### **3 Archived Datasets**

For this DSIC, tabulations were completed using the dataset “anal.sas7bdat”, an analysis file provided to the NIDDK repository by the DCC. We did not use the original form-based variables – rather we used the variables as contained in the analysis file. All analyses were conducted using Stata v12. We converted the SAS analysis file to Stata format using StatTransfer (Circle Systems).

## 4 DSIC Analysis

Our DSIC analyses compare our tabulations to published results in Table 2 (Baseline Characteristics by Individual Treatment Group), Table 3 (Primary End Point: Change from Baseline to 6 Weeks in Total Score NIH-CPSI), Table 5 (Secondary End Points: Changes from Baseline to 6 Weeks Individual Groups) and Figure 2, Mean values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH\_CPSI) total score (potential of 43 points) over time for the 4 individual treatment groups.

Descriptive statistics are presented for the change in NIH-CPSI total score and subscores over treatment groups and time. The mean change from baseline to 6 weeks is presented for all patients who had complete data at both time points. For the secondary longitudinal end points, only the mean change from baseline is shown. In the manuscript, p values (Table 4) were derived from longitudinal regression models with treatment-by-time interaction terms; we did not perform these statistical tests in the DSIC.

## 5 DSIC Results

Distributions of baseline characteristics by individual treatment groups matched published results exactly (Table 2). Consequently, only one set of results is presented.

**Table 1: Baseline Characteristics by Individual Treatment Groups (Table 2).**

Characteristic	data var name	Alexander et al (2004)			
		Placebo	Ciprofloxacin	Tamsulosin	Combination
<b>Patients, n</b>	<i>arm</i>	49	49	49	49
<b>Ethnicity, n(%)</b>	<i>race</i>				
<b>White</b>		26 (53)	35 (71)	34 (69)	32 (65)
<b>Black or African American</b>		6 (12)	10 (20)	6 (12)	9 (18)
<b>Hispanic</b>		11 (22)	4 (8)	4 (8)	7 (14)
<b>Other†</b>		6 (12)	0 (0)	5 (10)	1 (2)
<b>Age, y</b>	<i>age</i>	42.6 ± 12	45.9 ± 11.7	45.3 ± 9.7	44.5 ± 11.4
<b>Time since diagnosis, y</b>	<i>duration</i>	6.7 ± 7.3	6.7 ± 7.2	6.3 ± 7.7	5 ± 6
<b>NIH-CPSI‡</b>					
<b>Total score</b>	<i>cpsi</i>	25 ± 5.1	24.2 ± 6.2	24.6 ± 6.2	25.3 ± 6.1
<b>Pain score</b>	<i>pain</i>	12.2 ± 3	11.7 ± 3.1	11.3 ± 3.6	12 ± 3.4
<b>Urinary score</b>	<i>urinary</i>	4.5 ± 2.5	4.8 ± 2.8	5.1 ± 2.9	5 ± 2.4
<b>Quality of life score</b>	<i>qol</i>	8.3 ± 1.9	7.7 ± 2.2	8.2 ± 2.2	8.2 ± 2.3
<b>Medical Outcomes Study</b>					
<b>Mental summary score</b>	<i>mcs12</i>	41.6 ± 12.7	46.3 ± 11.6	45.7 ± 9.1	47.5 ± 12.3
<b>Physical summary score</b>	<i>pcs12</i>	45.4 ± 9.2	45.3 ± 8.2	43.9 ± 9.8	44.9 ± 9.2

\* Values presented with a plus/minus sign are means ± SD.

NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index.

† Includes Asian, Pacific Islander, Native American, and multiracial.

‡ Scores on the NIH-CPSI represent the average of two baseline scores. The ranges of possible scores on the 3 NIH-CPS domains are as follows: pain = 0-21 points; urinary = 0-10 points; quality of life = 0-12 points. The total score ranges from 0 to 43 points. The 3 domain scores may not sum to the total score because of rounding.

Note: our tabulations for DSIC exactly matched the published result. Published results reported in Alexander et al (2004) Ann Intern Med 141(8):583.




## 6 Primary and Secondary Outcomes

The primary outcome was the change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) from baseline to 6 weeks. The NIH-CPSI total score ranges from 0 to 43 points; a high score indicates more severe symptoms.

Tabulations of mean values of the NIH-CPSI by individual treatment groups over time appear to match exactly the published results as plotted in Figure 2 of the manuscript. Mean values calculated by the DSIC for Figure 2 are presented as a supplemental table for comparative purposes.

**Figure 1: Mean values of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score (potential of 43 points) over time for the 4 individual treatment groups (Figure 2).**



	Placebo	Ciprofloxacin	Tamsulosin	Combination
<b>0</b>	24.9	24.2	24.6	25.3
<b>3</b>	21.7	18.8	20.9	20.6
<b>6</b>	21.9	17.9	20	20.9
<b>9</b>	21.2	17.9	18.9	20.7
<b>12</b>	21.7	18.6	18.7	20.7

Secondary outcomes included changes in the pain, voiding, and quality-of-life subscales on the NIH-CPSI and physical and mental summary scores on the Medical Outcomes Study 12-Item Short Form Health

Survey. Participants who withdrew from the study before 6 weeks were defined as treatment nonresponders and were included in the denominator for the assessment of response rates.

For the NIH-CPSI, higher scores indicate more severe symptoms (for the quality-of-life score, higher scores indicate a more negative effect). Score ranges are as follows: total score, 0 to 43; pain score, 0 to 21; urinary score, 0 to 10, quality-of-life score, 0 to 12. For the Medical Outcomes Study Short Form Health Survey 12 (SF-12), higher scores indicate better quality of life. Score range for both the physical and mental component summaries is 0 to 100.

The end points of secondary symptoms and quality of life are shown in Tables 4 and 5. DSIC results (Ns, percentages, means and standard deviations) matched exactly the published tabulations indicating no significant effects of drug treatment at 6 weeks for either ciprofloxacin (compared to no ciprofloxacin) or tamsulosin (compared to no tamsulosin). P values for the differences in secondary end points by treatment (ciprofloxacin and tamsulosin) in the DSIC tabulations were calculated using standard t-test and were slightly higher than the values derived from longitudinal regression models in the published analyses. As these values were not tabulated using the same statistical procedure, they are not presented in the results below.

**Table 2: Secondary end points: Changes from baseline to 6 weeks, main effects (Table 4).**

Symptom Score	Ciprofloxacin			Tamsulosin		
	No	Yes	P value	No	Yes	P value
<b>Patients, n</b>	98	98		98	98	
<b>Respondents, n (%) †</b>	23 (24)	16 (16)	> 0.2	22 (23)	17 (17)	> 0.2
<b>Patients with complete data at 6 weeks, n (%) ‡</b>	90 (92)	84 (84)		87 (89)	87 (89)	
<b>NIH-CPSI §</b>						
<b>Total score</b>	-3.9 ± 5.7	-5.2 ± 6.8	0.15	-4.7 ± 6.4	-4.3 ± 6.1	> 0.2
<b>Pain score</b>	-1.9 ± 3.3	-2.4 ± 4.2	> 0.2	-2.3 ± 3.8	-2.0 ± 3.7	> 0.2
<b>Urinary score</b>	-0.7 ± 2.0	-1.2 ± 2.0	0.1	-0.9 ± 2.1	-1.0 ± 1.9	> 0.2
<b>Quality of life score</b>	-1.2 ± 1.8	-1.6 ± 2.2	0.2	-1.5 ± 2.0	-1.3 ± 2.0	> 0.2
<b>Medical Outcomes Study 12-item Short form Survey</b>						
<b>Mental composite score</b>	1.2 ± 10.1	-0.9 ± 8.9	0.19	0.8 ± 9.7	0.5 ± 9.5	> 0.2
<b>Physical composite score</b>	2.7 ± 7.2	2.6 ± 7.6	>0.2	2.0 ± 7.3	3.3 ± 7.4	0.17

**Note:** P values presented in the manuscript were based on a treatment-by-treatment (by time) interaction; these statistical tests were not performed in the DSIC

\* Values presented with a plus/minus sign are means ± SD. NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index

† Patients who withdrew before 6 weeks were considered nonresponders and were included in the denominator for the calculation of response rates in an intention-to-treat analysis.

‡ Means ± SDs for symptom and quality-of-life end points include only the 174 patients who had complete data at both baseline and 6 weeks. Thus, this analysis excludes the 17 patients who withdrew from study before 6 weeks as well as 5 patients who continued in the study but missed the clinic visit at 6 weeks for various reasons. P values are derived from the longitudinal regression models that included all available data on all patients. These results do not represent an intention-to-treat analysis and should be interpreted cautiously because of the potential bias related to patient withdrawal from the study.

§ The ranges of possible scores on the 3 NIH-CPSI domains are as follows: pain, 0-21; urinary, 0-10; quality of life, 0-12. Total possible score ranges from 0 to 43 points. A negative change indicates improvement. The 3 domain scores may not sum to the total score because of rounding.

Note: Published results reported in Alexander et al (2004) Ann Intern Med 141(8):586

**Table 3: Secondary end points: Changes from baseline to 6 weeks in individual groups (Table 5).**

<b>Variable</b>	<b>Placebo Group</b>	<b>Ciprofloxacin Group</b>	<b>Tamsulosin Group</b>	<b>Combination Group</b>
<b>Patients, n</b>	49	49	49	49
<b>Respondents, n (%) †</b>	11 (22)	11 (22)	12 (24)	5 (10)
<b>Patients with complete data at 6 weeks, n (%) ‡</b>	45 (92)	42 (86)	45 (92)	42 (86)
<b>NIH-CPSI §</b>				
<b>Total score</b>	-3.4 ± 5	-6.2 ± 7.3	-4.4 ± 6.3	-4.1 ± 6.1
<b>Pain score</b>	-1.6 ± 2.9	-3.0 ± 4.6	-2.3 ± 3.7	-1.8 ± 3.7
<b>Urinary score</b>	-0.5 ± 2	-1.3 ± 2.1	-0.9 ± 2	-1.1 ± 1.8
<b>Quality of life score</b>	-1.2 ± 1.5	-1.9 ± 2.4	-1.3 ± 2.0	-1.3 ± 1.9
<b>Medical Outcomes Study 12-item Short form Survey</b>				
<b>Mental composite score</b>	2.7 ± 9.5	-1.2 ± 9.7	0.3 ± 10.6	-0.7 ± 8.3
<b>Physical composite score</b>	1.5 ± 6.6	2.5 ± 7.9	3.9 ± 7.5	2.7 ± 7.3

\* Values presented with a plus/minus sign are means ± SD. NIH-CPSI=National Institutes of Health Chronic Prostatitis Symptom Index.

† Patients who withdrew before 6 weeks were considered nonresponders and were included in the denominator for the calculation of response rates in an intention-to-treat analysis.

‡ Means ± SDs for symptom and quality-of-life end points include only the 174 patients who had complete data at both baseline and 6 weeks. Thus, this analysis excludes the 17 patients who withdrew from study before 6 weeks as well as 5 patients who continued in the study but missed the clinic visit at 6 weeks for various reasons. P values are derived from the longitudinal regression models that included all available data on all patients. These results do not represent an intention-to-treat analysis and should be interpreted cautiously because of the potential bias related to patient withdrawal from the study.

§ The ranges of possible scores on the 3 NIH-CPSI domains are as follows: pain = 0-21; urinary = 0-10; quality of life = 0-12. Total possible score ranges from 0 to 43 points. A negative change indicates improvement. The 3 domain scores may not sum to the total score because of rounding.

Note: Published results reported in Alexander et al (2004) Ann Intern Med 141(8):586 and replicated by DSIC.

## **7 Summary**

Descriptive results provided by this DSIC for the baseline measurements and the primary and secondary outcomes were tabulated using an analysis file provided by the DCC to the NIDDK repository. DSIC results either matched exactly or closely agreed with published values in Alexander et al (2004).

## 8 References

1. Alexander RB, Probert KJ, Schaeffer AJ et al (2004). Ciprofloxacin or Tamsulosin in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. *Annals of Internal Medicine* 141:581-589.
2. [2]. Users of the data are referred to the document 'Primary manuscript.sas' provided by the DCC to the NIDDK repository which provides SAS code and variable definition for the anal.sas7bdat file used in reproducing the tables in the Alexander et al. manuscript.

## Appendix A: Stata Code and Output for DSIC Tabulations

```

-----
log: C:\Documents and Settings\smr\My
Documents\CPCRN\CPCRN_CiproFlomax_FinalPacket\DSIC\DSIC results.log
log type: text
opened on: 6 Mar 2012, 17:29:49

. *****Replicate tables in Alexander et al 2004*****
. *****Ciproflomax or Tamsulosin in Men with Chronic Prostatitis/Chronic Pelvic Pain
Syndrome*****
.
. use "anal.dta", clear

. ****Table 2. Baseline characteristics by individual treatment groups
.
. tab1 arm racecat

-> tabulation of arm

      arm |      Freq.      Percent      Cum.
-----+-----
      A |          224          25.17          25.17
      B |          225          25.28          50.45
      C |          222          24.94          75.39
      D |          219          24.61         100.00
-----+-----
    Total |          890         100.00

-> tabulation of racecat

      racecat |      Freq.      Percent      Cum.
-----+-----
         2 |          144          16.18          16.18
         3 |          114          12.81          28.99
         5 |          576          64.72          93.71
        99 |           56           6.29         100.00
-----+-----
    Total |          890         100.00

. encode arm, gen(group)

. label define group 1"placebo" 2"tamsulosin" 3"combined" 4"ciprofoxacina", replace

. tab arm group

      arm |      placebo  tamsulosi  combined  ciprofoxa |      Total
-----+-----
      A |          224           0           0           0 |          224
      B |           0          225           0           0 |          225
      C |           0           0          222           0 |          222
      D |           0           0           0          219 |          219
-----+-----
    Total |          224          225          222          219 |          890

. label list group
group:

```

CPCRN-CiproFlomax

1 placebo  
 2 tamsulosin  
 3 combined  
 4 ciprofoxacin

. label define race 2"Black" 3"Latino/Hisp" 5"White" 99"other"

. label value race race

. sort group

. tab vnum

vnum	Freq.	Percent	Cum.
2	196	22.02	22.02
3	182	20.45	42.47
4	174	19.55	62.02
5	169	18.99	81.01
6	169	18.99	100.00
Total	890	100.00	

. tab group if vnum==2

group	Freq.	Percent	Cum.
placebo	49	25.00	25.00
tamsulosin	49	25.00	50.00
combined	49	25.00	75.00
ciprofoxacin	49	25.00	100.00
Total	196	100.00	

. tab group race if vnum==2, col

```
+-----+
| Key   |
+-----+
|       |
| frequency |
| column percentage |
+-----+
```

group	racecat				Total
	Black	Latino/Hi	White	other	
placebo	6 19.35	11 42.31	26 20.47	6 50.00	49 25.00
tamsulosin	6 19.35	4 15.38	34 26.77	5 41.67	49 25.00
combined	9 29.03	7 26.92	32 25.20	1 8.33	49 25.00
ciprofoxacin	10 32.26	4 15.38	35 27.56	0 0.00	49 25.00
Total	31 100.00	26 100.00	127 100.00	12 100.00	196 100.00



CPCRN-CiproFlomax

. tabstat age if vnum==2, by (group) stat (mean sd min max median)

Summary for variables: age  
by categories of: group

group	mean	sd	min	max	p50
placebo	42.63265	12.02028	24	72	40
tamsulosin	45.26531	9.669056	24	67	44
combined	44.5102	11.44757	23	70	45
ciprofoxacine	45.93878	11.68583	25	71	48
Total	44.58673	11.22441	23	72	44

. \*\*VNUM visit 2, Randomization Visit

. tabstat duration cpsi pain urinary quol mcs12 pcs12 if vnum==2, by (group) stat (mean sd)

Summary statistics: mean, sd  
by categories of: group

group	duration	cpsi	pain	urinary	quol	mcs12	pcs12
placebo	6.72449	24.96939	12.19388	4.5	8.27551	41.60305	45.37933
	7.321986	5.057388	2.970017	2.462214	1.944708	12.73736	9.195978
tamsulosin	6.334043	24.55102	11.28571	5.061224	8.204082	45.71337	43.89307
	7.741595	6.162931	3.608439	2.895098	2.247495	9.149324	9.762405
combined	4.959574	25.2551	12.02041	4.989796	8.244898	47.52845	44.94521
	5.997197	6.056266	3.423204	2.427039	2.343258	12.32879	9.218835
ciprofoxacine	6.727083	24.20408	11.67347	4.816327	7.714286	46.28448	45.27458
	7.171033	6.195528	3.126751	2.758876	2.217356	11.57027	8.200557
Total	6.194764	24.7449	11.79337	4.841837	8.109694	45.28234	44.87305
	7.071654	5.855195	3.284682	2.631756	2.188421	11.65668	9.060733

. \*\*\*\*\*Table 3. Primary End Point: Change from Baseline to 6 weeks in Total Score NIH-CPSI

. tab group test1 if vnum==4

group	test1		Total
	0	1	
placebo	45	0	45
tamsulosin	45	0	45
combined	0	42	42
ciprofoxacine	0	42	42
Total	90	84	174

. tab group test2 if vnum==4

group	test2		Total
	0	1	
placebo	45	0	45
tamsulosin	0	45	45

CPCRN-CiproFlomax

combined	0	42	42
ciprofoxacin	42	0	42
Total	87	87	174

. tabstat d\_cpsi if vnum==4, by (group) stat (mean sd)

Summary for variables: d\_cpsi  
by categories of: group

group	mean	sd
placebo	-3.366667	5.029911
tamsulosin	-4.402222	6.258684
combined	-4.142857	6.082046
ciprofoxacin	-6.154762	7.303932
Total	-4.494828	6.232121

. tabstat d\_cpsi if vnum==4, by (test1) stat (mean sd)

Summary for variables: d\_cpsi  
by categories of: test1

test1	mean	sd
0	-3.884444	5.66961
1	-5.14881	6.756425
Total	-4.494828	6.232121

. tabstat d\_cpsi if vnum==4, by (test2) stat (mean sd)

Summary for variables: d\_cpsi  
by categories of: test2

test2	mean	sd
0	-4.712644	6.351447
1	-4.277011	6.139497
Total	-4.494828	6.232121

.  
. keep if vnum<=4  
(338 observations deleted)

. gen week=.  
(552 missing values generated)

. replace week=0 if vnum==2  
(196 real changes made)

. replace week=3 if vnum==3  
(182 real changes made)

. replace week=6 if vnum==4  
(174 real changes made)

. tab week vnum



CPCRN-CiproFlomax

. tabl cipro flomax

-> tabulation of cipro

cipro	Freq.	Percent	Cum.
0	280	50.72	50.72
1	272	49.28	100.00
Total	552	100.00	

-> tabulation of flomax

flomax	Freq.	Percent	Cum.
0	274	49.64	49.64
1	278	50.36	100.00
Total	552	100.00	

. tabl cipro flomax if vnum==4

-> tabulation of cipro if vnum==4

cipro	Freq.	Percent	Cum.
0	90	51.72	51.72
1	84	48.28	100.00
Total	174	100.00	

-> tabulation of flomax if vnum==4

flomax	Freq.	Percent	Cum.
0	87	50.00	50.00
1	87	50.00	100.00
Total	174	100.00	

. tabstat d\_cpsi if vnum==4, by (cipro) stat (mean sd n)

Summary for variables: d\_cpsi  
by categories of: cipro

cipro	mean	sd	N
0	-3.884444	5.66961	90
1	-5.14881	6.756425	84
Total	-4.494828	6.232121	174

. ttest d\_cpsi if vnum==4, by (cipro)

Two-sample t test with equal variances

Group	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf. Interval]
0	90	-3.884444	.5976293	5.66961	-5.071921 -2.696968
1	84	-5.14881	.7371864	6.756425	-6.615044 -3.682575
combined	174	-4.494828	.4724559	6.232121	-5.427348 -3.562308

CPCRN-CiproFlomax

```
-----+-----
diff |          1.264365    .9433049                -.5975794    3.12631
-----+-----
diff = mean(0) - mean(1)                                t =    1.3404
Ho: diff = 0                                           degrees of freedom =    172

Ha: diff < 0                Ha: diff != 0                Ha: diff > 0
Pr(T < t) = 0.9091          Pr(|T| > |t|) = 0.1819          Pr(T > t) = 0.0909
```

. ttest d\_pain if vnum==4, by (cipro)

Two-sample t test with equal variances

```
-----+-----
Group |      Obs      Mean   Std. Err.   Std. Dev.   [95% Conf. Interval]
-----+-----
0 |      90     -1.94   .3510349   3.330209   -2.637499   -1.242501
1 |      84     -2.39881 .4590034   4.206836   -3.311749   -1.48587
-----+-----
combined |    174   -2.161494 .2861654   3.774781   -2.726319   -1.596669
-----+-----
diff |          .4588095    .5732672                -.6727353    1.590354
-----+-----
diff = mean(0) - mean(1)                                t =    0.8003
Ho: diff = 0                                           degrees of freedom =    172

Ha: diff < 0                Ha: diff != 0                Ha: diff > 0
Pr(T < t) = 0.7877          Pr(|T| > |t|) = 0.4246          Pr(T > t) = 0.2123
```

. ttest d\_ur if vnum==4, by (cipro)

Two-sample t test with equal variances

```
-----+-----
Group |      Obs      Mean   Std. Err.   Std. Dev.   [95% Conf. Interval]
-----+-----
0 |      90    -.7055556 .2055556   1.950071   -1.11399   -.297121
1 |      84    -1.14881 .2140336   1.96165   -1.574514   -.7231054
-----+-----
combined |    174   -.9195402 .1487857   1.962618   -1.213209   -.6258713
-----+-----
diff |          .443254    .2966939                -.142376    1.028884
-----+-----
diff = mean(0) - mean(1)                                t =    1.4940
Ho: diff = 0                                           degrees of freedom =    172

Ha: diff < 0                Ha: diff != 0                Ha: diff > 0
Pr(T < t) = 0.9315          Pr(|T| > |t|) = 0.1370          Pr(T > t) = 0.0685
```

. ttest d\_quol if vnum==4, by (cipro)

Two-sample t test with equal variances

```
-----+-----
Group |      Obs      Mean   Std. Err.   Std. Dev.   [95% Conf. Interval]
-----+-----
0 |      90    -1.238889 .1876705   1.780399   -1.611786   -.8659916
1 |      84    -1.60119 .2411336   2.210026   -2.080796   -1.121585
-----+-----
combined |    174   -1.413793 .1517518   2.001743   -1.713316   -1.11427
-----+-----
diff |          .3623016    .3033102                -.2363879    .9609911
-----+-----
diff = mean(0) - mean(1)                                t =    1.1945
Ho: diff = 0                                           degrees of freedom =    172
```

CPCRN-CiproFlomax

Ha: diff < 0                      Ha: diff != 0                      Ha: diff > 0  
 Pr(T < t) = 0.8830                  Pr(|T| > |t|) = 0.2339                  Pr(T > t) = 0.1170

. ttest d\_mcs if vnum==4, by (cipro)

Two-sample t test with equal variances

Group	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf. Interval]	
0	90	1.16713	1.064965	10.10315	-.9489327	3.283193
1	84	-.931467	.9738199	8.925206	-2.868356	1.005422
combined	174	.1540143	.7264935	9.583107	-1.279918	1.587946
diff		2.098597	1.449265		-.7620371	4.959231

diff = mean(0) - mean(1)    t = 1.4480  
 Ho: diff = 0    degrees of freedom = 172

Ha: diff < 0                      Ha: diff != 0                      Ha: diff > 0  
 Pr(T < t) = 0.9253                  Pr(|T| > |t|) = 0.1494                  Pr(T > t) = 0.0747

. ttest d\_pcs if vnum==4, by (cipro)

Two-sample t test with equal variances

Group	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf. Interval]	
0	90	2.678492	.7547515	7.160202	1.178816	4.178167
1	84	2.609196	.8258495	7.569036	.9666148	4.251778
combined	174	2.645039	.5563759	7.339102	1.54688	3.743198
diff		.0692954	1.116633		-2.134774	2.273365

diff = mean(0) - mean(1)    t = 0.0621  
 Ho: diff = 0    degrees of freedom = 172

Ha: diff < 0                      Ha: diff != 0                      Ha: diff > 0  
 Pr(T < t) = 0.5247                  Pr(|T| > |t|) = 0.9506                  Pr(T > t) = 0.4753

. ttest d\_cpsi if vnum==4, by (flomax)

Two-sample t test with equal variances

Group	Obs	Mean	Std. Err.	Std. Dev.	[95% Conf. Interval]	
0	87	-4.712644	.6809466	6.351447	-6.066321	-3.358967
1	87	-4.277011	.6582231	6.139497	-5.585516	-2.968507
combined	174	-4.494828	.4724559	6.232121	-5.427348	-3.562308
diff		-.4356322	.9470723		-2.305013	1.433749

diff = mean(0) - mean(1)    t = -0.4600  
 Ho: diff = 0    degrees of freedom = 172

Ha: diff < 0                      Ha: diff != 0                      Ha: diff > 0  
 Pr(T < t) = 0.3231                  Pr(|T| > |t|) = 0.6461                  Pr(T > t) = 0.6769

. ttest d\_pain if vnum==4, by (flomax)



CPCRN-CiproFlomax

```
-----+-----
combined |      174      .1540143      .7264935      9.583107      -1.279918      1.587946
-----+-----
diff |              1.342583      1.453604              -1.526618      4.211783
-----+-----
```

```
diff = mean(0) - mean(1)                                t =      0.9236
Ho: diff = 0                                           degrees of freedom =      172
```

```
Ha: diff < 0                                Ha: diff != 0                                Ha: diff > 0
Pr(T < t) = 0.8215                          Pr(|T| > |t|) = 0.3570                      Pr(T > t) = 0.1785
```

. ttest d\_pcs if vnum==4, by (flomax)

Two-sample t test with equal variances

```
-----+-----
Group |      Obs      Mean      Std. Err.      Std. Dev.      [95% Conf. Interval]
-----+-----
0 |      87      1.976949      .7771756      7.249011      .4319746      3.521922
1 |      87      3.313129      .7943763      7.409448      1.733961      4.892297
-----+-----
combined |      174      2.645039      .5563759      7.339102      1.54688      3.743198
-----+-----
diff |              -1.33618      1.111321              -3.529765      .8574039
-----+-----
```

```
diff = mean(0) - mean(1)                                t =     -1.2023
Ho: diff = 0                                           degrees of freedom =      172
```

```
Ha: diff < 0                                Ha: diff != 0                                Ha: diff > 0
Pr(T < t) = 0.1154                          Pr(|T| > |t|) = 0.2309                      Pr(T > t) = 0.8846
```

. tab sym1 vnum

```
-----+-----+-----+-----+-----
sym1 |              vnum
-----+-----+-----+-----+-----
      2      3      4 |      Total
-----+-----+-----+-----+-----
0 |      0      2      2 |      4
1 |      6      5      5 |     16
2 |     22      9     13 |     44
3 |    132     73     55 |    260
4 |     28     65     60 |    153
5 |      6     22     30 |     58
6 |      2      3      9 |     14
-----+-----+-----+-----+-----
Total |     196     179     174 |    549
```

. tab cipro if sym1>=5 & vnum==4

```
-----+-----+-----+-----
cipro |      Freq.      Percent      Cum.
-----+-----+-----+-----
0 |      23      58.97      58.97
1 |      16      41.03     100.00
-----+-----+-----+-----
Total |      39     100.00
```

. tab flomax if sym1>=5 & vnum==4

```
-----+-----+-----+-----
flomax |      Freq.      Percent      Cum.
-----+-----+-----+-----
0 |      22      56.41      56.41
1 |      17      43.59     100.00
-----+-----+-----+-----
```



CPCRN-CiproFlomax

Total | 39 100.00

```
.
.
. *****Table 5. Secondary End Points: Changes from Baseline to 6 weeks,
Individual groups
. tab group if vnum==4
```

group	Freq.	Percent	Cum.
placebo	45	25.86	25.86
tamsulosin	45	25.86	51.72
combined	42	24.14	75.86
ciprofoxacin	42	24.14	100.00
Total	174	100.00	

```
. tabstat d_cpsi if vnum==4, by (group) stat (mean sd)
```

Summary for variables: d\_cpsi  
by categories of: group

group	mean	sd
placebo	-3.366667	5.029911
tamsulosin	-4.402222	6.258684
combined	-4.142857	6.082046
ciprofoxacin	-6.154762	7.303932
Total	-4.494828	6.232121

```
. tabstat d_pain if vnum==4, by (group) stat (mean sd)
```

Summary for variables: d\_pain  
by categories of: group

group	mean	sd
placebo	-1.611111	2.868102
tamsulosin	-2.268889	3.739702
combined	-1.761905	3.738785
ciprofoxacin	-3.035714	4.584429
Total	-2.161494	3.774781

```
. tabstat d_ur if vnum==4, by (group) stat (mean sd)
```

Summary for variables: d\_ur  
by categories of: group

group	mean	sd
placebo	-.5333333	1.95518
tamsulosin	-.8777778	1.95156
combined	-1.047619	1.823992
ciprofoxacin	-1.25	2.107623
Total	-.9195402	1.962618

```
. tabstat d_quol if vnum==4, by (group) stat (mean sd)
```

```
Summary for variables: d_quol
by categories of: group
```

group	mean	sd
placebo	-1.222222	1.498316
tamsulosin	-1.255556	2.041118
combined	-1.333333	1.940162
ciprofoxacin	-1.869048	2.444655
Total	-1.413793	2.001743

```
. tabstat d_mcs if vnum==4, by (group) stat (mean sd)
```

```
Summary for variables: d_mcs
by categories of: group
```

group	mean	sd
placebo	2.677613	9.477956
tamsulosin	-.3433529	10.58151
combined	-.7036242	8.247571
ciprofoxacin	-1.15931	9.650531
Total	.1540143	9.583107

```
. tabstat d_pcs if vnum==4, by (group) stat (mean sd)
```

```
Summary for variables: d_pcs
by categories of: group
```

group	mean	sd
placebo	1.48452	6.64458
tamsulosin	3.872464	7.525675
combined	2.713842	7.325626
ciprofoxacin	2.504551	7.892446
Total	2.645039	7.339102

```
. tab group if syml>=5 & vnum==4
```

group	Freq.	Percent	Cum.
placebo	11	28.21	28.21
tamsulosin	12	30.77	58.97
combined	5	12.82	71.79
ciprofoxacin	11	28.21	100.00
Total	39	100.00	

CPCRN-CiproFlomax

```
.
. *****Figure 2. Mean values of the NIH CPSI total score over time by
individual treatment group
. tabulate vnum arm, summarize(cpsi)
```

Means, Standard Deviations and Frequencies of cpsi

vnum	arm				Total
	A	B	C	D	
2	24.969388	24.55102	25.255102	24.204082	24.744898
	5.0573875	6.1629309	6.0562661	6.1955279	5.8551949
	49	49	49	49	196
3	21.713636	20.902128	20.577778	18.803488	20.515922
	6.9749582	7.1321528	9.1066631	6.8212587	7.5815703
	44	47	45	43	179
4	21.911111	20.031111	20.952381	17.880952	20.22069
	6.0408542	7.5527184	9.1517088	8.740716	7.9972848
	45	45	42	42	174
Total	22.934058	21.892199	22.378676	20.489179	21.932149
	6.1850479	7.1819622	8.3799797	7.762081	7.4481854
	138	141	136	134	549

```
.
.
end of do-file
```

```
. log close
```

```
log type: text
closed on: 6 Mar 2012, 17:30:32
```